Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 11/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.61 |
| ▸ | ITK | Q08881 | 1/20 | 0.59 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.56 |
| ▸ | TTK | P33981 | 3/20 | 0.55 |
| ▸ | SGK1 | O00141 | 1/20 | 0.55 |
| ▸ | UQCRB | P14927 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461030 | 0.91 | AURKA (0.67) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL5381750 | 0.88 | MAP2K4 (0.68) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1460566 | 0.85 | AURKA (0.64) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1460621 | 0.84 | TTK (0.65) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1460609 | 0.84 | MAPK1 (0.50) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1460585 | 0.83 | AURKA (0.63) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1460786 | 0.83 | MAP2K4 (0.68) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1459765 | 0.83 | AURKA (0.68) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1461117 | 0.83 | AURKB (0.59) | AURKAAURKBITKMAP2K4TTK | |
| SCHEMBL1459779 | 0.83 | AURKA (0.60) | AURKAAURKBITKMAP2K4TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4643910-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | claimed |
| JP-2005533004-A | — | — | 2005-11-04 | — | — | JP | claimed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | claimed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | claimed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| EP-1487803-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
| WO-2003078402-A1 | INDAZOLES SUBSTITUTED WITH AN ANTI-CANCEROUS ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | AURKA 17/4885AURKB 33/4885ITK 222/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | AURKA 65/4885AURKB 67/4885ITK 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.